🏅 FDA Orphan Designation
Ampyra
dalfampridine
Manufacturer: Acorda Therapeutics
Indicated for:
FDA-Approved Indications (1)
NON RARE IN EUROPE: Multiple sclerosisOrphan Designation
Treatment to improve walking in patients with multiple sclerosis
Indications & Usage
1 INDICATIONS AND USAGE AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ]. AMPYRA ® (dalfampridine) is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed ( 1 , 14 ).
💙 Support Programs
View all →AMPYRA
Acorda
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.